AIM IMMUNOTECH INC.

AIM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Aug 2026 Jun 2026 May 2026 Mar 2026 Mar 2026 Dec 2025 Nov 2025 Sep 2025
Revenue $26.0K $22.0K $26.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $589.0K $482.0K $607.0K
SG&A Expense $2.9M $1.8M $1.8M
Operating Income $-3.5M $-2.2M $-2.4M
Operating Margin -13,511.5% -10,118.2% -9,411.5%
Interest Expense $295.0K $304.0K $148.0K
Pretax Income
Income Tax Expense
Net Income $-3.8M $-3.0M $-3.3M
Net Margin -14,569.2% -13,740.9% -12,630.8%
EPS (Basic) $-0.43 $-0.69 $0.52
EPS (Diluted) $-0.43 $-0.69 $0.52
Shares Outstanding (Basic) 30.4M 17.1M 14.6M 4.4M 8.1M 3.1M 8.6M 6.3M
Shares Outstanding (Diluted) 30.4M 17.1M 14.6M 4.4M 8.1M 3.1M 8.6M 6.3M
Dividends Per Share
← Newer Page 1 of 16 Older →